Skip to main content
Top
Published in: Medical Oncology 3/2015

01-03-2015 | Original Paper

Downregulation of UPK1A suppresses proliferation and enhances apoptosis of bladder transitional cell carcinoma cells

Authors: Haiyan Zhu, Yuxin Tang, Xiangyang Zhang, Xianzhen Jiang, Yong Wang, Yu Gan, Jianfu Yang

Published in: Medical Oncology | Issue 3/2015

Login to get access

Abstract

Uroplakin 1A (UPK1A) is a specific marker of mammalian urothelium and one of major proteins contained in urothelial plaques. Many recent studies reported that UPK1A could be useful marker for diagnosis, detection and prognostic prediction of transitional cell carcinoma. However, relatively little is known about its exact roles in bladder transitional cell carcinoma (BTCC). We tried to explore the roles UPK1A plays in BTCC via the transfection of its antisense nucleotides (AS) into T24 cells to observe their changes of proliferation and apoptosis. After AS was successfully transfected into T24 cells, the percentages of proliferating T24 cells at 24 and 48 h after the treatment were 57.2 ± 6.8 and 44.7 ± 5.2 %, significantly lower than that of control group, as shown by MTT (p < 0.05 and 0.01). At 24 h after transfection of AS, the percentage of apoptotic T24 cells was 26.87 % measured by flow cytometry, significantly higher than that of control group (p < 0.01). Similarly, Hoechst 33258 staining showed that the percentage of apoptotic nuclei of T24 cells after 24 h treated by AS was 28.9 %, significantly higher than that of control (p < 0.05). The most common and typical morphological changes of apoptosis, including shrink, pyknosis and karyorrhexis of T24 cells nuclei and DNA fragmentation were seen from Hoechst 33258 staining and DNA agarose gel electrophoresis. Taken together, inhibition of UPK1A can suppress proliferation and enhance apoptosis of BTCC T24 cells, suggesting it a potential target to treat this disease.
Literature
2.
go back to reference Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control J Moffitt Cancer Center. 2000;7(4):325–34. Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control J Moffitt Cancer Center. 2000;7(4):325–34.
3.
go back to reference Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995;153(6):1823–6 (discussion 6–7).CrossRefPubMed Holmang S, Hedelin H, Anderstrom C, Johansson SL. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J Urol. 1995;153(6):1823–6 (discussion 6–7).CrossRefPubMed
4.
go back to reference Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996;156(6):1934–40, (discussion 40–41). Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol. 1996;156(6):1934–40, (discussion 40–41).
9.
go back to reference Sun TT, Liang FX, Wu XR. Uroplakins as markers of urothelial differentiation. Adv Exp Med Biol. 1999;462:7–18 (discussion 103–114).CrossRefPubMed Sun TT, Liang FX, Wu XR. Uroplakins as markers of urothelial differentiation. Adv Exp Med Biol. 1999;462:7–18 (discussion 103–114).CrossRefPubMed
10.
go back to reference Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol. 2003;199(1):41–9. doi:10.1002/path.1252.CrossRefPubMed Olsburgh J, Harnden P, Weeks R, Smith B, Joyce A, Hall G, et al. Uroplakin gene expression in normal human tissues and locally advanced bladder cancer. J Pathol. 2003;199(1):41–9. doi:10.​1002/​path.​1252.CrossRefPubMed
11.
go back to reference Li SM, Zhang ZT, Chan S, McLenan O, Dixon C, Taneja S, et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol. 1999;162(3 Pt 1):931–5.CrossRefPubMed Li SM, Zhang ZT, Chan S, McLenan O, Dixon C, Taneja S, et al. Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder. J Urol. 1999;162(3 Pt 1):931–5.CrossRefPubMed
12.
go back to reference Wu RL, Osman I, Wu XR, Lu ML, Zhang ZF, Liang FX, et al. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res. 1998;58(6):1291–7.PubMed Wu RL, Osman I, Wu XR, Lu ML, Zhang ZF, Liang FX, et al. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. Cancer Res. 1998;58(6):1291–7.PubMed
13.
go back to reference Daniel PT, Sturm I, Ritschel S, Friedrich K, Dorken B, Bendzko P, et al. Detection of genomic DNA fragmentation during apoptosis (DNA ladder) and the simultaneous isolation of RNA from low cell numbers. Anal Biochem. 1999;266(1):110–5. doi:10.1006/abio.1998.2929.CrossRefPubMed Daniel PT, Sturm I, Ritschel S, Friedrich K, Dorken B, Bendzko P, et al. Detection of genomic DNA fragmentation during apoptosis (DNA ladder) and the simultaneous isolation of RNA from low cell numbers. Anal Biochem. 1999;266(1):110–5. doi:10.​1006/​abio.​1998.​2929.CrossRefPubMed
14.
go back to reference Kageyama S, Yoshiki T, Isono T, Tanaka T, Kim CJ, Yuasa T, et al. High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res Gann. 2002;93(5):523–31.CrossRefPubMed Kageyama S, Yoshiki T, Isono T, Tanaka T, Kim CJ, Yuasa T, et al. High expression of human uroplakin Ia in urinary bladder transitional cell carcinoma. Jpn J Cancer Res Gann. 2002;93(5):523–31.CrossRefPubMed
15.
go back to reference Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147(5):1383–97.PubMedCentralPubMed Moll R, Wu XR, Lin JH, Sun TT. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. Am J Pathol. 1995;147(5):1383–97.PubMedCentralPubMed
16.
go back to reference Yuasa T, Yoshiki T, Isono T, Tanaka T, Okada Y. Molecular cloning and expression of uroplakins in transitional cell carcinoma. Adv Exp Med Biol. 2003;539(Pt A):33–46.PubMed Yuasa T, Yoshiki T, Isono T, Tanaka T, Okada Y. Molecular cloning and expression of uroplakins in transitional cell carcinoma. Adv Exp Med Biol. 2003;539(Pt A):33–46.PubMed
17.
go back to reference Xu X, Sun TT, Gupta PK, Zhang P, Nasuti JF. Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens. Cancer. 2001;93(3):216–21.CrossRefPubMed Xu X, Sun TT, Gupta PK, Zhang P, Nasuti JF. Uroplakin as a marker for typing metastatic transitional cell carcinoma on fine-needle aspiration specimens. Cancer. 2001;93(3):216–21.CrossRefPubMed
19.
go back to reference Osman I, Kang M, Lee A, Deng FM, Polsky D, Mikhail M, et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer. 2004;111(6):934–9. doi:10.1002/ijc.20366.CrossRefPubMed Osman I, Kang M, Lee A, Deng FM, Polsky D, Mikhail M, et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int J Cancer. 2004;111(6):934–9. doi:10.​1002/​ijc.​20366.CrossRefPubMed
20.
go back to reference Yuasa T, Yoshiki T, Isono T, Tanaka T, Hayashida H, Okada Y. Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol Off J Jpn Urol Assoc. 1999;6(6):286–92. Yuasa T, Yoshiki T, Isono T, Tanaka T, Hayashida H, Okada Y. Expression of transitional cell-specific genes, uroplakin Ia and II, in bladder cancer: detection of circulating cancer cells in the peripheral blood of metastatic patients. Int J Urol Off J Jpn Urol Assoc. 1999;6(6):286–92.
21.
go back to reference Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284(5756):555–6.CrossRefPubMed Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284(5756):555–6.CrossRefPubMed
22.
go back to reference Slagsvold HH, Marvik OJ, Eidem G, Kristoffersen N, Paulsen RE. Detection of high molecular weight DNA fragments characteristic of early stage apoptosis in cerebellar granule cells exposed to glutamate. Exp Brain Res. 2000;135(2):173–8.CrossRefPubMed Slagsvold HH, Marvik OJ, Eidem G, Kristoffersen N, Paulsen RE. Detection of high molecular weight DNA fragments characteristic of early stage apoptosis in cerebellar granule cells exposed to glutamate. Exp Brain Res. 2000;135(2):173–8.CrossRefPubMed
Metadata
Title
Downregulation of UPK1A suppresses proliferation and enhances apoptosis of bladder transitional cell carcinoma cells
Authors
Haiyan Zhu
Yuxin Tang
Xiangyang Zhang
Xianzhen Jiang
Yong Wang
Yu Gan
Jianfu Yang
Publication date
01-03-2015
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2015
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-015-0541-y

Other articles of this Issue 3/2015

Medical Oncology 3/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.